Inovio Pharmaceuticals ( ($INO) ) has provided an announcement. On December 29, 2025, INOVIO announced that the U.S. Food and Drug Administration ...

This study offers important insight into the pathogenic basis of intragenic frameshift deletions in the carboxy-terminal domain of MECP2, which account for some Rett syndrome cases, yet similar ...

As we close out 2025, I am excited to reflect on a year marked by significant clinical progress, robust data validation, and strategic execution that has significantly strengthened IMUNON's position.

Learn more about whether Charles River Laboratories International, Inc. or Danaher Corporation is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial ...

By Henry A. Onwubiko“A nation that cannot control its own seeds cannot decide its destiny.” –Captain Ibrahim Troure Genetic engineering, the manipulation of deoxyribonucleic acid (DNA), the hereditary ...

Maintaining CDK4/6 inhibition constrains drug‑resistant breast tumors by delaying cell‑cycle entry, and adding CDK2 inhibition further deepens control to guide post‑progression therapy.